Growth deficits in children with attention deficit hyperactivity disorder

Pediatrics

Volumn 102, Issue 2 III, 1998, Pages 501-506

  Spencer, Thomas ^a   Biederman, Joseph ^b   Wilens, Timothy ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

Attention deficit hyperactivity disorder; Growth deficit; Height deficit; Stimulant; Weight deficit

Indexed keywords

CATECHOLAMINE; CENTRAL STIMULANT AGENT; PSYCHOTROPIC AGENT;

ARTICLE; ATTENTION DEFICIT DISORDER; BODY HEIGHT; CATCH UP GROWTH; GROWTH RETARDATION; MALNUTRITION; NEUROENDOCRINE SYSTEM; NEUROTRANSMISSION; PRIORITY JOURNAL; SHORT STATURE;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; GROWTH; GROWTH DISORDERS; HUMANS;

EID: 0031927349     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Castellanos F, Giedd J, Marsh W, et al. Quantitative brain magnetic resonance imaging in attention deficit hyperactivity disorder. Arch Gen Psychiatry. 1996;53:607-616
2. Zametkin AJ, Nordahl TE, Gross M, et al. Cerebral glucose metabolism in adults with hyperactivity of childhood onset. N Engl J Med. 1990;323: 1361-1366
3. Biederman J, Faraone SV, Keenan K, et al. Further evidence for family-genetic risk factors in attention deficit hyperactivity disorder (ADHD): patterns of comorbidity in probands and relatives in psychiatrically and pediatrically referred samples. Arch Gen Psychiatry. 1992;49:728-738
4. Zametkin AJ, Rapoport JL. Noradrenergic hypothesis of attention deficit disorder with hyperactivity: a critical review. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press; 1987:837-842
5. Spencer TJ, Biederman J, Wilens T, Harding M, O'Donnell D, Griffin S. Pharmacotherapy of ADHD across the lifecycle: a literature review. J Am Acad Child Adolesc Psychiatry. 1996;35:409-432
6. Ranke MB, Blum WF, Bierich JR. Clinical relevance of serum measurements of insulin-like growth factors and somatomedin binding proteins. Acta Paediatr Scand Suppl. 1988;347:114-126
7. Lurie S, O'Quinn A. Neuroendocrine responses to methylphenidate and d-amphetamine: applications to attention-deficit disorder. J Neuropsychiatry. 1991;3:41-50
8. Garfinkel B, Brown W, Klee S, Braden W, Beauchesne R, Shapiro S. Neuroendocrine and cognitive responses to amphetamine in adolescents with a history of attention deficit disorder. J Am Acad Child Adolesc Psychiatry. 1986;25:503-508
9. Aarskog D, Fevang F, Klove H, Stoa F, Thorsen T. The effect of the stimulant drugs, dextroamphetamine and methylphenidate, on secretion of growth hormone in hyperactive children. Pediatrics. 1977;90: 136-139
10. Shaywitz SE, Hunt RD, Jatlow P, et al. Psychopharmacology of attention deficit disorder: pharmacokinetic, neuroendocrine, and behavioral measures following acute and chronic treatment with methylphenidate. Pediatrics. 1982;69:688-694
11. Gualtieri CT, Kanoy R, Hawk B, et al. Growth hormone and prolactin secretion in adults and hyperactive children: relation to methylphenidate serum levels. Psychoneuroendocrinology. 1981;6:331-339
12. Greenhill LL, Puig-Antich J, Chambers W, Rubinstein B, Halpern F, Sachar EJ. Growth hormone, prolactin, and growth responses in hyperkinetic males treated with d-amphetamine. J Am Acad Child Psychiatry. 1981;20:84-103
13. Weizman R, Dick J, Gil A, Weitz R, Tyano S, Laron Z. Effects of acute and chronic methylphenidate administration on beta-endorphin, growth hormone, prolactin and cortisol in children with attention deficit disorder and hyperactivity. Life Sci. 1987;40:2247-2252
14. Hunt RD, Cohen DJ, Anderson G, Clark L. Possible change in noradrenergic receptor sensitivity following methylphenidate treatment: growth hormone and MHPG response to clonidine challenge in children with attention deficit disorder and hyperactivity. Life Sci. 1984;35: 885-897
15. Schultz F, Hayford J, Wolraich M, Hintz R, Thompson R. Methylphenidate treatment of hyperactive children: effects on the hypothalamic-pituitary-somatomedin axis. J Pediatr. 1982;70:987-992
16. Shaywitz BA, Shaywitz SE, Sebrechts M, et al. Growth hormone and prolactin response to methylphenidate in children with attention deficit disorder. Life Sci. 1990;46:625-633
17. Greenhill LL, Puig-Antich J, Novacenko MA, Solomon M. Prolactin, growth hormone and growth responses in boys with attention deficit disorder and hyperactivity treated with methylphenidate. J Am Acad Child Psychiatry. 1984;23:58-67
18. Dickinson LC, Lee J, Ringdahl IC, Schedewie HK, Kilgore BS, Elders MJ. Impaired growth in hyperkinetic children receiving pemoline. Pediatrics. 1979;94:538-541
19. Kilgore BS, Dickinson MA, Burnett CR, Lee J, Schedewie HK, Elders MJ. Alterations in cartilage metabolism by neurostimulant drugs. J Pediatr. 1979;94:542-545
20. Rosenfield RL. Somatic growth and maturation. In: DeGroot LJ, Besser GM, Cahill GF Jr, et al, eds. Endocrinology. Philadelphia, PA: WB Saunders; 1989:2242-2282
21. Leibowitz SF. The role of serotonin in eating disorders. Drugs. 1990; 39(suppl 3):33-48
22. Blundell JE. Appetite disturbance and the problems of overweight. Drugs. 1990;39(suppl 3):1-19, 63-66
23. Safer D, Allen R. Factors influencing the suppressant effects of two stimulant drugs on the growth of hyperactive children. J Pediatr. 1973; 51:660-667
24. Satterfield JH, Cantwell DP, Schell A, Blaschke T. Growth of hyperactive children treated with methylphenidate. Arch Gen Psychiatry. 1979; 36:212-217
25. Mattes JA, Gittelman R. Growth of hyperactive children on maintenance regimen of methylphenidate. Arch Gen Psychiatry. 1983;40: 317-321
26. Safer DJ, Allen RP, Barr E. Depression of growth in hyperactive children on stimulant drugs. N Engl J Med. 1972;287:217-220
27. Safer D, Allen R, Barr E. Growth rebound after termination of stimulant drugs. J Pediatr. 1975;86:113-116
28. Loney J, Whaley KMA, Ponto LB, Adney K. Predictors of adolescent height and weight in hyperkinetic boys treated with methylphenidate Psychopharmacol Bull. 1981;17:132-134. Proceedings
29. Weiss G, Kruger E, Danielson U, Elman M. Effect of long-term treatment of hyperactive children with methylphenidate. Can Med Assoc J. 1975;112:159
30. Gittelman R, Landa B, Mattes J, Klein D. Methylphenidate and growth in hyperactive children: a controlled withdrawal study. Arch Gen Psychiatry. 1988;45:1127-1130
31. Spencer T, Biederman J, Wright V, Danon M. Growth deficits in children treated with desipramine: a controlled study. J Am Acad Child Adolesc Psychiatry. 1992;31:235-243
32. Eisenberg L. The hyperkinetic child and stimulant drugs. N Engl J Med. 1972;287:249-250
33. Quinn PO, Rapoport JL. One-year follow-up of hyperactive boys treated with imipramine or methylphenidate. Am J Psychiatry. 1975;132:241-245
34. Millichap JG, Millichap M. Growth of hyperactive children. N Engl J Med. 1975;292:1300
35. Gross M. Growth of hyperkinetic children taking methylphenidate, dextroamphetamine, or imipramine/desipramine. J Pediatr. 1976;58: 423-431
36. McNutt BA, Boileau RA, Cohen MN. The effects of long-term stimulant medication on the growth and body composition of hyperactive children. Psychopharmacology. 1977;13:36-38
37. Millichap JG. Dr Gross's findings supported. Pediatrics. 1978;61:146-147
38. Kalachnik JE, Sprague RL, Sleator EK, Cohen MN, Ullmann RK. Effect of methylphenidate hydrochloride on stature of hyperactive children. Dev Med Child Neurol. 1982;70:987-992
39. Vincent J, Varley C, Leger P. Effects of methylphenidate on early adolescent growth. Am J Psychiatry. 1990;147:501-502
40. Greenhill LL, Puig-Antich J, Sassin J, Sachar EJ. Hormone and growth responses in hyperkinetic children on stimulant medication Psychopharmacology. 1977;13:33-36. Proceedings
41. Puig-Antich J, Greenhill LL, Sassin J, Sachar EJ. Growth hormone, prolactin, and cortisol responses and growth patterns in hyperkinetic children treated with dextroamphetamine. J Am Acad Child Adolesc Psychiatry. 1978;20:84-103
42. Friedmann N, Thomas J, Carr R, Elders J, Ringdahl I, Roche A. Effect on growth in pemoline-treated children with attention deficit disorder. Am J Dis Child. 1981;135:329-332
43. Chinchilli VM, McEnery PT, Chan JCM. Statistical methods and determination of sample size in the growth failure in children with renal diseases study. J Pediatr. 1990;116(suppl):S32-S36
44. Spencer T, Biederman J, Harding M, O'Donnell D, Faraone S, Wilens T. Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays? J Am Acad Child Adolesc Psychiatry. 1996;35: 1460-1469
45. Polito C, Oporto MR, Torino SF, La Manna A, Di Toro R. Normal growth of nephrotic children during long-term alternate-day prednisone therapy. Acta Paediatr Scand. 1986;75:245-250
46. Hamill PVV, Drizd TA, Johnson CL, Reed R, Roche A. Physical growth: National Center for Health Statistics percentiles. Am J Clin Nutr. 1979; 32:607-629
47. Goldstein H. Sampling for growth studies. In: Falkner F, Tanner J, eds. Human Growth. New York, NY: Plenum Press; 1978:183-208
48. Hechtman L, Weiss G, Perlman T. Young adult outcome of hyperactive children who received long-term stimulant treatment. J Am Acad Child Psychiatry. 1984;23:261-269
49. Gittelman R, Mannuzza S. Hyperactive boys almost grown up. III. Methylphenidate effects on ultimate height. Arch Gen Psychiatry. 1988; 45:1131-1134
50. Safer DJ. A familial factor in minimal brain dysfunction. Behav Genet. 1973;3:175-186
51. Marshall W, Tanner J. Puberty. In: Falkner F, Tanner J, eds. Human Growth: A Comprehensive Treatise. 2nd ed. New York, NY: Plenum Press; 1986:171-209
52. Tanner J, Davies P. Clinical longitudinal standards for height and height velocity for North American children. J Pediatr. 1985;107:317-329